Recent Updates
Recently added Catalysts

Waters Corporation

WATFDA catalysts, PDUFA dates & pipeline intelligence
$456.48
▼ -9.62 · -2.06%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full WAT financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $282.7752W HIGH $483.33
Volume
1.02 M
Value Traded
468.86 M
Short % Float
3.39%
Days to Cover
3.6
-1.24%Week
+3.08%1 Month
+12.8%3 Month
+33.87%6 Month
+9.67%5 Year
+8,954.41%All Time

Cash Data

Unlock WAT cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
44.87 B
EPS (TTM)
0.50
P/E Ratio
913.51
Ent. Value
48.76 B
Total Shares
98.29 M
Float Shares
98.15 M
Insiders
0.14%
Institutions
101.60%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every WAT catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

WAT Catalyst Timeline

Dated clinical, regulatory and corporate events for Waters Corporation

Catalyst Timeline

Dated clinical, regulatory & corporate events for Waters Corporation

196Total events
9Upcoming
26Tier-1 (high impact)
2011 to 2027Coverage

Upcoming catalysts 2

T2Product Launch
Subscribe to view catalyst details
T2Quarterly Update
Subscribe to view catalyst details

Event history 50

▲FDA ApprovalFDA Decision
FDA 510(k) clearance of BD OneFlow B-CLPD T1 Test for B-cell NHL/CLL identification
B-cell non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL)source ↗
▲FDA ApprovalFDA Decision
FDA 510(k) clearance of BD OneFlow LST Test for B-cell NHL/CLL identification
B-cell non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL)source ↗
▲Quarterly UpdateCorporate
Waters reports third quarter 2026 financial results
▲AcquiredCorporate
Waters acquires MOBILion Systems, adding SLIM ion mobility technology
◆Timing GuidancePresentation
Management to provide 2027 starting growth framework on earnings call
▲Product LaunchPost-Market
Waters launches AI-Powered Peak Integration for Empower Software
▲Partnership / LicenseCorporate
Waters and Labcorp announce partnership to expand access to BD Onclarity HPV Assay
cervical cancer screening (HPV testing)source ↗
▲Partnership / LicenseCorporate
Waters and Quest Diagnostics collaboration to broaden access to Onclarity Self-Collection Kit
cervical cancer screening (HPV)source ↗
▲Partnership / LicenseCorporate
UG200 Sequencing Platform selected to power large-scale immune profiling study with IMU Biosciences and UK Biobank
▲Partnership / LicenseCorporate
Waters joins Anthropic's Model Hardware Standard (MHS) research program
Unlock the full WAT catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How WAT actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all WAT historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

Waters Corporation is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every WAT program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every WAT trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock WAT insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
KUEBLER CHRISTOPHER ADirectorOption 3,626 21,434 held$136.43 08/06/2026
Unlock the full WAT insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
PERCEPTIVE ADVISORS LLC 1 % 59.32 M 135.00 K
Unlock every fund holding WAT
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in WAT
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see WAT ownership
Insider and institutional ownership, quarter by quarter.

WAT Short Interest

Shares sold short, counted twice a month.

3.39%
Short % of Float
of tradable shares sold short
3.3M
Shares Sold Short
+4.3% vs prior count
3.6 Moderate
Days to Cover
trading days of normal volume to buy every short share back
916.4K
Avg Daily Volume
the average used for days to cover
Unlock WAT short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock WAT option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live WAT option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock WAT options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How WAT ranks across every disease it competes in

Competitive Position is a premium feature
See how WAT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

WAT News

WAT
Nov 17, 2026
WATConferences/Events
▼ -2.1%today

Waters Corporation to Present at the 9th Annual Evercore Healthcare Conference

Waters Corporation announced that CEO Udit Batra will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on December 1, 2026. The event will be accessible via a live webcast, which will also be available for replay for 90 days. The company continues to focus on advancing life sciences through innovative technologies.

Read more →
WAT
Nov 10, 2026
WATFDA Updates

Waters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma

Waters Corporation announced FDA 510(k) clearance for the BD OneFlow LST and B-CLPD T1 Tests, which aid in diagnosing B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. These tests provide 96.3% sensitivity and 98.2% specificity, while significantly reducing manual steps in the testing process. They are set to be commercially available in spring 2027.

Read more →
WAT
Nov 3, 2026
WATGeneral

Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results

Waters Corporation reported third quarter 2026 revenue of $1.767 billion, exceeding guidance. Adjusted EPS rose 21% to $4.10, driven by strong growth in both Analytical Sciences and Biosciences divisions. The company raised its full-year revenue guidance by $43 million, citing new growth vectors. Additionally, Waters announced the acquisition of MOBILion Systems, enhancing its capabilities in proteomics.

Read more →
WAT
Nov 3, 2026
WATGeneral

Waters Acquires MOBILion Systems, Bringing Advanced Ion-Mobility Separation to its Mass Spectrometry Portfolio with the Speed and Resolution AI Workflows Require for Proteomics Biomarker Discovery

Waters Corporation has acquired MOBILion Systems to enhance its mass spectrometry portfolio with SLIM high-resolution ion mobility technology. This acquisition aims to accelerate Waters' entry into the proteomics market, improving molecular analysis and supporting AI-driven research. The integration of SLIM technology is expected to advance clinical applications for biomarker discovery and blood-based diagnostics.

Read more →
WAT
Oct 28, 2026
WATGeneral

Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software

Waters Corporation has launched AI-Powered Peak Integration, enhancing its Empower Software for chromatography data processing. This new feature significantly reduces manual interventions by up to 95% and improves accuracy by 76%. It aims to support regulated laboratories in speeding up drug development while maintaining data integrity. Early access for customers begins in December 2026.

Read more →
WAT
Oct 23, 2026
WATGeneral

Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026

Waters Corporation and Labcorp announced a partnership to provide the FDA-approved BD Onclarity HPV Assay, enhancing cervical cancer screening access. This initiative aims to address screening gaps by offering both clinician-collected and self-collected testing options. The assay supports all ASCCP guidelines and provides extensive genotyping, making it a significant advancement in cervical cancer prevention.

Read more →
WAT
Oct 20, 2026
WATGeneral

Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option

Waters Corporation and Quest Diagnostics announced a collaboration to expand access to the FDA-cleared Onclarity Self-Collection Kit for HPV testing. Starting in 2027, Quest will distribute the at-home kit through its national clinician, health plan, and consumer channels. This initiative targets the 24 million un- and under-screened individuals in the U.S. by offering a convenient, comprehensive screening option.

Read more →
WAT
Oct 19, 2026
WATGeneral

Ultima Genomics Selected for Landmark Large-Scale Immune Profiling Study with IMU Biosciences, UK Biobank and Waters Corporation

Ultima Genomics has been selected to provide its UG200 Sequencing Platform for a large-scale immune profiling study in collaboration with IMU Biosciences and UK Biobank. The study aims to analyze 80,000 blood samples, contributing to a comprehensive dataset that will enhance understanding of the human immune system. This initiative is expected to expand to a total of 500,000 samples, facilitating advanced research into immune-related diseases.

Read more →
WAT
Oct 13, 2026
WATGeneral

Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release

Waters Corporation has launched Waters AI Link, a new software capability that integrates AI into laboratory workflows. This innovation allows for AI-directed experiments to transition seamlessly from research to regulated environments, enhancing efficiency and reducing timelines. The company has also joined Anthropic's Model Hardware Standard program, facilitating autonomous operation of laboratory instruments. This advancement positions Waters as a leader in the AI transformation of laboratory processes.

Read more →
WAT
Oct 1, 2026
WATConferences/Events

Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call

Waters Corporation has announced its Q3 2026 earnings conference call scheduled for November 3, 2026. The call will begin at 8:00 a.m. Eastern Time and will be available via a live webcast. A replay of the presentation will be accessible until December 1, 2026.

Read more →
WAT
Sep 14, 2026
WATGeneral

Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer

Waters Corporation has launched the BD FACSDiscover A7 Cell Analyzer, enhancing flow cytometry capabilities with advanced spectral resolution and standardization. This new device allows researchers to conduct experiments with over 50 parameters, improving data consistency across different users and instruments. The analyzer is designed to facilitate immunology research and drug development, making advanced technologies more accessible.

Read more →
WAT
Sep 11, 2026
WATConferences/Events

Waters Corporation to Present at the J.P. Morgan U.S. All Stars Conference

Waters Corporation will have its CEO, Udit Batra, participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference on September 23, 2026. The event will be webcast live and available for replay for 90 days. This participation underscores Waters' commitment to engaging with investors and stakeholders.

Read more →
WAT
Aug 31, 2026
WATGeneral

Wellinks Appoints Andrew Agwunobi and Mike Waters to Board of Directors and Expands Management Team

Wellinks has appointed Andrew Agwunobi and Mike Waters to its Board of Directors, alongside three new leadership roles. These appointments aim to enhance the company's operational excellence and support its growth in virtual cardiopulmonary care. The new leaders bring extensive experience in healthcare and technology to strengthen Wellinks' impact on patient care.

Read more →
WAT
Aug 26, 2026
WATConferences/Events

Waters Corporation to Present at the Wells Fargo Healthcare Conference

Waters Corporation announced that its CEO, Udit Batra, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026. The event will be available via live webcast, with a replay accessible for 90 days. This participation underscores Waters' leadership in life sciences and commitment to innovation.

Read more →
WAT
Aug 4, 2026
WATGeneral
▲ +5.7%on this news

Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

Waters Corporation reported strong financial results for Q2 2026, with total revenue of $1.645 billion, surpassing guidance. Organic revenue grew by 9% in constant currency, driven by significant growth in the Analytical Sciences Division. The company raised its full-year guidance, reflecting positive market conditions and effective execution of its growth strategy. However, GAAP EPS showed a loss due to acquisition-related costs.

Read more →
WAT
Jul 27, 2026
WATGeneral

Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer

Waters Corporation has launched the Xevo TQ Absolute XR IVD Mass Spectrometer, enhancing its MassTrak IVD System portfolio. This new system offers five times greater sensitivity than its competitors, improving analytical performance for complex biological samples. It is designed for routine laboratory testing in women's health, cancer assessment, and toxicology, promising to boost laboratory productivity and reliability.

Read more →
WAT
Jul 2, 2026
WATConferences/Events

Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call

Waters Corporation has announced its Q2 2026 earnings conference call scheduled for August 4, 2026. The call will take place at 8:00 a.m. Eastern Time, with a live webcast available on the company's Investor Relations website. A replay of the call will be accessible until September 1, 2026.

Read more →
WAT
Jun 25, 2026
WATGeneral

SNT Biotech Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients

SNT Biotech has partnered with Waters Corporation to enhance access to at-home cervical cancer screenings through the FDA-cleared Onclarity™ HPV Self-Collection Kit. This initiative aims to address the significant barriers to screening faced by underserved populations, with a focus on improving completion rates and early detection of cervical cancer. The partnership combines education and infrastructure to facilitate better health outcomes for women.

Read more →
WAT
Jun 24, 2026
WATGeneral

IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine

IMU Biosciences has partnered with Waters Corporation to enhance its AI-driven immune mapping platform. This collaboration aims to analyze over 100 million data points from a single blood sample, improving early diagnosis and precision medicine. The partnership will leverage Waters' advanced technologies to expand IMU's immune dataset and establish new standards in immune profiling.

Read more →
WAT
Jun 23, 2026
WATGeneral

HighRes® and Waters Collaborate to Advance Drug Discovery through Robotic Automation

Waters Corporation is collaborating with HighRes® to enhance drug discovery processes through robotic automation. This partnership aims to streamline workflows and improve efficiency in pharmaceutical research. The collaboration highlights the ongoing trend of integrating advanced technologies in drug development.

Read more →

About Waters Corporation

Milford, MA 7,900 employees waters.com
Headquarters34 MAPLE ST, MILFORD, MA, 01757
BIOPHARMAWATCH ELITE
Trade the next WAT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime